206 related articles for article (PubMed ID: 3223973)
1. Comparative pharmacokinetics of isosorbide nitrates after repeated doses of sustained release isosorbide dinitrate.
Laufen H; Leitold M; Wildfeuer A
Arzneimittelforschung; 1988 Sep; 38(9):1336-41. PubMed ID: 3223973
[TBL] [Abstract][Full Text] [Related]
2. [Bioavailability and bioequivalence of organic nitrates. Isosorbide dinitrate--a study of sustained-release preparations].
Scheidel B; Blume H; Stenzhorn G; Siewert M; Babej-Dölle RM
Arzneimittelforschung; 1991 Mar; 41(3):212-8. PubMed ID: 1867657
[TBL] [Abstract][Full Text] [Related]
3. Lack of bioequivalence between different formulations of isosorbide dinitrate and hydralazine and the fixed-dose combination of isosorbide dinitrate/hydralazine: the V-HeFT paradox.
Tam SW; Sabolinski ML; Worcel M; Packer M; Cohn JN
Clin Pharmacokinet; 2007; 46(10):885-95. PubMed ID: 17854237
[TBL] [Abstract][Full Text] [Related]
4. [Bioavailability of isosorbide dinitrate and isosorbide-5-mononitrate under steady-state conditions].
Rietbrock N; Knoll J; Merz PG; Menke G
Dtsch Med Wochenschr; 1985 Nov; 110(47):1821-5. PubMed ID: 3905327
[TBL] [Abstract][Full Text] [Related]
5. Bioavailability of isosorbide dinitrate and its two mononitrate metabolites from sustained-release formulations.
Chasseaud LF; Doyle E; Taylor T; Darragh A; Lambe RF
Int J Clin Pharmacol Ther Toxicol; 1983 Oct; 21(10):514-8. PubMed ID: 6642789
[TBL] [Abstract][Full Text] [Related]
6. [Comparative pharmacokinetics and bioavailability of isosorbide dinitrate and its metabolites isosorbide 5- and 2-mononitrate from delayed-release preparations].
Geigenberger A; Degen J; Maier-Lenz H
Arzneimittelforschung; 1982; 32(9):1138-40. PubMed ID: 6890839
[TBL] [Abstract][Full Text] [Related]
7. Plasma concentrations of isosorbide dinitrate after oral administration of a sustained-release formulation to human subjects.
Assinder DF; Chasseaud LF; Hunter JO; Jung RJ; Taylor T
Arzneimittelforschung; 1977; 27(1):156-8. PubMed ID: 576817
[TBL] [Abstract][Full Text] [Related]
8. [Comparative study of the bioavailability and pharmacokinetics of isosorbide dinitrate formulations in retard form and in standard preparations by determination of isosorbide-5-mononitrate].
Lutz VD; Gielsdorf W; Rasper J; Jaeger H; Loew D
Arzneimittelforschung; 1985; 35(4):730-4. PubMed ID: 4015739
[TBL] [Abstract][Full Text] [Related]
9. [Bioavailability of sustained-release and nonsustained-release isosorbide-5-mononitrate].
Muck B; Bonn R; Rietbrock N
Arzneimittelforschung; 1989 Oct; 39(10):1274-6. PubMed ID: 2610720
[TBL] [Abstract][Full Text] [Related]
10. Bioavailability and metabolism of isosorbide dinitrate from a transdermal spray.
Laufen H; Leitold M
Arzneimittelforschung; 1992 Jul; 42(7):931-5. PubMed ID: 1418058
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of isosorbide dinitrate and isosorbide-5-mononitrate.
Schaumann W
Int J Clin Pharmacol Ther Toxicol; 1989 Sep; 27(9):445-53. PubMed ID: 2681004
[TBL] [Abstract][Full Text] [Related]
12. Bioavailability and pharmacokinetics of a new isosorbide dinitrate spray preparation in healthy volunteers.
Hutt V; Theodor R; Pabst G; Lutz D; Bonn R; Fritschi E
Arzneimittelforschung; 1993 Aug; 43(8):842-6. PubMed ID: 8216439
[TBL] [Abstract][Full Text] [Related]
13. Serum concentrations of isosorbide dinitrate produced by a sustained-release capsule.
Halkin H; Almog S; Friedman E
Isr J Med Sci; 1979 May; 15(5):448-50. PubMed ID: 447513
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of isosorbide-5-mononitrate after oral administration of an extended-release mononitrate formulation versus a standard dinitrate formulation.
Kosoglou T; Patrick JE; Cohen A; Radwanski E; Christopher D; Affrime MB
Clin Ther; 1995; 17(2):241-51. PubMed ID: 7614524
[TBL] [Abstract][Full Text] [Related]
15. [Bioavailability of isosorbide-5-mononitrate from delayed-action formulations].
Taylor T; Major RM; Leaf FC; Cook SC; Chasseaud LF; Darragh A; Lambe RF
Arzneimittelforschung; 1984; 34(11):1584-7. PubMed ID: 6543135
[TBL] [Abstract][Full Text] [Related]
16. Plasma concentrations of isosorbide dinitrate after administration of increasing doses of a sustained-release formulation to human subjects.
Taylor T; O'Kelly DA; Major RM; Darragh A; Chasseaud LF
Arzneimittelforschung; 1978; 28(8):1426-8. PubMed ID: 582411
[TBL] [Abstract][Full Text] [Related]
17. [Pharmacokinetic profile and bioavailability of a new pharmaceutical formulation of isosorbide-5-mononitrate sustained-release formulation].
Skutta T; Böttcher B; Brandt L
Arzneimittelforschung; 1989 Apr; 39(4):507-11. PubMed ID: 2751738
[TBL] [Abstract][Full Text] [Related]
18. [Study of the bioequivalence of a new isosorbide dinitrate tablet formulation compared with the standard preparation].
Metzner JE; Buchberger D; Häring N; Läuter J
Arzneimittelforschung; 1997 Jun; 47(6):719-26. PubMed ID: 9281301
[TBL] [Abstract][Full Text] [Related]
19. [Pharmacodynamic effects of the sustained-release tablet of isosorbide dinitrate and its bioavailability in conscious dogs (author's transl)].
Kogi K; Chida S; Kimura T; Saito T
Nihon Yakurigaku Zasshi; 1980 Mar; 76(2):99-107. PubMed ID: 7399370
[TBL] [Abstract][Full Text] [Related]
20. [Hemodynamic effects of a transdermal formulation of isosorbide dinitrate and its pharmacokinetics in conscious dogs].
Kogi K; Tanaka O; Kimura T; Saito T
Nihon Yakurigaku Zasshi; 1982 Oct; 80(4):279-88. PubMed ID: 7152395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
